EEB: EGFR Exon 20 Insertions: Recent Findings, Laboratory Considerations, and Clinical Implications

EGFR Exon 20 Insertions

This webinar is a recorded presentation of a live broadcast and includes a pre-test, the presentation, audience Q&A, handout, and a post-test. Continuing Education is available for the webinar.


The epidermal growth factor receptor (EGFR) gene encodes a receptor tyrosine kinase. In NSCLC numerous hotspot mutations within the tyrosine kinase domain led to constitutive activation and oncogenesis. Unlike classical TKI sensitive mutations, exon 20 insertions (which account for ~5% of total) are resistant to 1st, 2nd and 3rd generation EGFR TKIs. However, newly approved targeted therapies options have recently become available and been shown to be effective therapeutic options when this variant type is present. The scientific background information, testing techniques, and clinical applications of this biomarker will be discussed.

Learning Objectives:
    • Describe the molecular biology of EGFR exon 20 mutations.
    • Identify technical challenges for the detection of EGFR exon 20 mutations.
    • Explain the clinical relevance of EGFR exon 20 mutations.

Eric Vail, MD

Cedars Sinai Medical Center


Jennifer Bynum, MD
Northside Hospital

Date Recorded: December 6, 2022
Duration: 1 Hour
Level of Instruction: Basic

This program has been supported through educational grant funding provided by Amgen and Loxo Oncology at Lilly (for further information concerning Lilly grant funding visit Supporting companies had no control over its content. No personally-identifiable information regarding you is provided to any grant supporters.

How to Register:
  1. Click the "Register Now" Button
  2. Log in using your AMP credentials. If you do not have an AMP account, Create a FREE account.
  3. Click on "Complete Registration" button
  4. Complete the "Demographic questionnaire for Emerging and Evolving Biomarkers Series" before the webinar date. You will only need to do this once for the entire series.

Continuing Education Credit Information

CME credit: 1.0
CMLE credit: 1.0 
Last day to claim credit: December 31, 2024

Accreditation Statements
AMA PRA Category 1 Credit(s)
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Note: Join the AMP Family for discounted access to the most current educational resources!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation.